Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function

Behavioural Brain Research

Volumn 153, Issue 2, 2004, Pages 507-519

  Duncan, Gary E ^a   Moy, Sheryl S ^a   Perez, Antonio ^a   Eddy, Dawn M ^a   Zinzow, Wendy M ^a   Lieberman, Jeffrey A ^a   Snouwaert, John N ^a   Koller, Beverly H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Model; Mouse; NMDA; Olfaction; Prepulse inhibition; Schizophrenia; Social behavior

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACOUSTICS; AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL TEST; EXPOSURE; FEMALE; GENETIC MODEL; HETEROZYGOTE; HOMOZYGOTE; HYBRID; HYPOTHESIS; MALE; MENTAL PATIENT; MOUSE; MUTANT; MUTATION; NONHUMAN; ODOR; PREDATOR; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SENSORIMOTOR NEUROPATHY; SOCIAL BEHAVIOR; STARTLE REFLEX; WILD TYPE;

AGONISTIC BEHAVIOR; ANIMALS; AROUSAL; ATTENTION; DISEASE MODELS, ANIMAL; FEAR; FEMALE; GYRUS CINGULI; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, NEUROLOGIC MUTANTS; MODELS, GENETIC; MOTIVATION; MOTOR CORTEX; NEURAL INHIBITION; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SENSORY THRESHOLDS; SOCIAL BEHAVIOR; SOCIAL ENVIRONMENT; SOMATOSENSORY CORTEX; STARTLE REACTION;

EID: 3242683236     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.01.008     Document Type: Article

References (47)

1. Acri J.B., Morse D.E., Popke E.J., Grunberg N.E. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology. 114:1994;369-374
2. Angrist B., Rotrosen J., Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology. 67:1980;31-38
3. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Therap. 283:1997;226-234
4. Arvanov V.L., Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Therap. 289:1999;1000-1006
5. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201
6. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Therap. 271:1994;787-794
7. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J. Neurosci. 22:2002;6713-6723
8. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl)lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II - symbolic and sequential thinking. Arch. Gen. Psychiatry. 6:1962;79-85
9. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74
10. Curzon P., Decker M.W. Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;129-146
11. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75
12. Duncan G.E., Miyamoto S., Gu H.B., Lieberman J.A., Koller B.H., Snouwaert J.N. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res. 951:2002;166-176
13. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Therap. 293:2000;8-14
14. Duncan G.E., Sheitman B.B., Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. - Brain Res. Rev. 29:1999;250-264
15. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 25:2000;284-288
16. Forrest D., Yuzaki M., Soares H.D., Ng L., Luk D.C., Sheng M., et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron. 13:1994;325-338
17. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154
18. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377
19. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 56:1999;21-27
20. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1213-1215
21. Hebb A.L.O., Zacharko R.M., Dominguez H., Laforest S., Gauthier M., Levac C., et al. Changes in brain cholecystokinin and anxiety-like behavior following exposure of mice to predator odor. Neuroscience. 116:2003;539-551
22. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry. 159:2002;480-482
23. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry. 169:1996;610-617
24. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 56:1999;29-36
25. Huerta P.T., Sun L.D., Wilson M.A., Tonegawa S. Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons. Neuron. 25:2000;473-480
26. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236
27. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
28. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214
29. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 6:1995;869-872
30. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19
31. Lahti A.C., Weiler M.A., Tamara M.B., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 25:2001;455-467
32. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 37:1994;4053-4067
33. Lieberman J.A., Kane J.M., Alvir J.A.J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433
34. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., Kelley R. Study of a new schizophrenomimeitc drug-sernyl. Arch. Neurol. Psych. 81:1959;363-369
35. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150
36. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition - the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307
37. Mansbach R.S., Carver J., Zorn S.H. Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol. Biochem. Behav. 69:2001;535-542
38. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit. J. Neurosci. 21:2001;750-757
39. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436
40. Nakazawa K., Quirk M.C., Chitwood R.A., Watanabe M., Yeckel M.F., Sun L.D., et al. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 297:2002;211-218
41. Paylor R., Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology. 132:1997;169-180
42. Schreiber R., Dalmus M., De Vry J. Effects of alpha(4)/beta(2)- and alpha(7)-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology. 159:2002;248-257
43. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacologia. 140:1998;75-80
44. Swerdlow N.R., Bakshi V.P., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Therap. 279:1996;1290-1299
45. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128:1996;371-379
46. Tsai G., Pinchen Y., Chung L.-C., Lange N., Coyle J.T. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089
47. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 87:1996;1327-1338